Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duvelisib + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Verastem Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen of **duvelisib**, an oral dual inhibitor of phosphoinositide 3-kinase delta (PI3K-δ) and gamma (PI3K-γ), and **obinutuzumab**, a glycoengineered humanized anti-CD20 type II monoclonal antibody. Duvelisib blocks PI3K-δ and -γ to inhibit cell proliferation and survival and interfere with the tumor microenvironment in hematologic malignancies. Obinutuzumab targets CD20-expressing B-cells, causing direct cell death and enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. The combination is under clinical investigation primarily for **chronic lymphocytic leukemia (CLL)** and **small lymphocytic lymphoma (SLL)**, especially in relapsed or refractory settings or in patients previously treated with Bruton’s tyrosine kinase inhibitors[2][3][4].
- Brand names
- Copiktra + Gazyva
- Other names
- duvelisib hydrochloride + obinutuzumab
02
Targets
PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)CD20 (B-lymphocyte antigen CD20)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on duvelisib + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duvelisib + obinutuzumab.